PhoreMost
PhoreMost is a biotechnology company developing a pipeline of small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need. The company's lead program, PMC-001, is an orally bioavailable microtubule disruptor designed to treat primary and metastatic brain cancers. Additionally, the firm utilizes proprietary chemistry against novel E3 ligases to develop next-generation bifunctional degraders for oncology and inflammation.
Visit websiteCambridge, UK
Biotechnology
Biopharmaceuticals
Oncology
Healthcare
Funding summary
- Total raised
- €39.1M
- Funding rounds
- 1
Investors in PhoreMost
Investors on record for PhoreMost. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like PhoreMost?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors